1 – 2 of 2
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
- Contribution to journal › Debate/Note/Editorial
- 2011
-
Mark
Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy
- Contribution to journal › Article